Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Garnier (2008)
Rebuilding the R&D engine in big pharma.Harvard business review, 86 5
J. Wilkinson, Bobbie Coleman (2001)
The legal and ethical considerations relating to the supply and use of human tissue for biomedical research: A UK perpectiveJournal of Commercial Biotechnology, 8
A. Nials, R. Coleman, M. Johnson, H. Magnussen, K. Rabe, C. Vardey (1993)
Effects of beta-adrenoceptor agonists in human bronchial smooth muscle.British journal of pharmacology, 110 3
A. Fujiyama, Hidemi Watanabe, A. Toyoda, T. Taylor, T. Itoh, S. Tsai, Hong-Seog Park, M. Yaspo, H. Lehrach, Zhu Chen, G. Fu, N. Saitou, K. Osoegawa, P. Jong, Y. Suto, M. Hattori, Y. Sakaki (2002)
Construction and analysis of a human-chimpanzee comparative clone map.Science, 295 5552
R. Shamburek, M. Schubert (1992)
Control of gastric acid secretion. Histamine H2-receptor antagonists and H+K(+)-ATPase inhibitors.Gastroenterology clinics of North America, 21 3
(2008)
Presumed consent law change ‘not necessary’ to donate organs
Robert Moore, Ayesha Khan, B. Dickey (1998)
Long-acting Inhaled β2-Agonists in Asthma TherapyChest, 113
A. Nials, Sorif Uddin (2008)
Mouse models of allergic asthma: acute and chronic allergen challengeDisease Models & Mechanisms, 1
D. Jack (1989)
The challenge of drug discovery.Drug design and delivery, 4 3
(2009)
Ministers struggle to combat shortages
(2008)
Drug companies: Big Pharma besieged from all sides. The Guardian
David Linsenbardt, Eileen Moore, Carly Gross, Karen Goldfarb, Laverne Blackman, S. Boehm (2009)
Sensitivity and tolerance to the hypnotic and ataxic effects of ethanol in adolescent and adult C57BL/6J and DBA/2J mice.Alcoholism, clinical and experimental research, 33 3
Susan Williams, R. Sullivan, H. Scott, D. Finkelstein, P. Colditz, B. Lingwood, P. Dodd, D. Pow (2005)
Glial glutamate transporter expression patterns in brains from multiple mammalian speciesGlia, 49
C. Persson (2002)
Con: mice are not a good model of human airway disease.American journal of respiratory and critical care medicine, 166 1
Cheryl Walker, S. Ahmed, Terry Brown, Shuk-Mei Ho, Leslie Hodges, G. Lucier, Jose Russo, Nancy Weigel, Tom Weise, John Vandenbergh, Gene Transription (1999)
Species, interindividual, and tissue specificity in endocrine signaling.Environmental Health Perspectives, 107
Amory Lovins, L. Lovins, P. Hawken (2008)
Una ruta hacia el capitalismo naturalHarvard Business Review, 86
N. Sakai, K. Saito, K. Sakamoto, M. Ishizuka, S. Fujita (2009)
Genetic Basis of Inter- and Intrastrain Differences in Diazepam p-Hydroxylation in RatsDrug Metabolism and Disposition, 37
W. Enard, P. Khaitovich, J. Klose, S. Zöllner, F. Heissig, Patrick Giavalisco, K. Nieselt-Struwe, E. Muchmore, A. Varki, R. Ravid, G. Doxiadis, R. Bontrop, S. Pääbo (2002)
Intra- and Interspecific Variation in Primate Gene Expression PatternsScience, 296
A. Nials, R. Coleman, M. Johnson, H. Magnussen, K. Rabe, C. Vardey (1993)
Effects of β‐adrenoceptor agonists in human bronchial smooth muscleBritish Journal of Pharmacology, 110
Panayiotis Tsaparas, L. Mariño-Ramírez, O. Bodenreider, E. Koonin, I. Jordan (2006)
- 1-Supplementary Information for : Global similarity and local divergence in human and mouse gene co-expression networks
L. Weyden, A. Bradley (2006)
Mouse chromosome engineering for modeling human disease.Annual review of genomics and human genetics, 7
R. Brittain, D. Jack (1983)
Histamine H2‐Antagonists‐Past, Present and FutureJournal of Clinical Gastroenterology, 5
R. Coleman (1999)
Current animal models are not predictive for clinical asthma.Pulmonary pharmacology & therapeutics, 12 2
J. Grisham (1997)
Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment.Carcinogenesis, 18 1
W. Abraham (2008)
Modeling of asthma, COPD and cystic fibrosis in sheep.Pulmonary pharmacology & therapeutics, 21 5
R. Coleman (2006)
Regulation and Practice of Human Tissue Research in the UK, 11
R. Moore, A. Khan, B. Dickey (1998)
Long-acting inhaled beta2-agonists in asthma therapy.Chest, 113 4
Today's drug discovery and development paradigm is not working, and something needs to be done about it. There is good reason to believe that a move away from reliance on animal surrogates for human subjects in the Pharma Industry's R&D programmes could provide an important step forward. However, no serious move will be made in that direction until there is some hard evidence that it will be rewarded with improved productivity outcomes. The Safer Medicines Trust are proposing that a study be undertaken, involving a range of drugs that have been approved for human use, but have subsequently proved to have limitations in terms of safety and/or efficacy. The aim is to determine the efficiency of a battery of human-based test methods to identify a compound's safety and efficacy profiles, and to compare this with that of the more traditional, largely animal-based methods that were employed in their original development. Should such an approach prove more reliable, the authorities will be faced with important decisions relating to the role of human biological test data in regulatory submissions, while the Pharma Industry will be faced with the key logistical issue of how to acquire the human biomaterials necessary to make possible the routine application of such test methods.
Alternatives to Laboratory Animals – SAGE
Published: Sep 1, 2009
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.